There is no published case series of harm from grey-market cagrilintide. That does not mean no harm has occurred — it means nobody has systematically recorded it.
To assess risk, you have to reason from adjacent evidence: adverse event records for compounded GLP-1 drugs, cases already documented on the same supply chain, and the arithmetic problems inherent to premixed vials.
[The known compounded GLP-1 adverse event numbers]
As of 31 May 2026, the FDA had recorded:
- Compounded semaglutide: 990 adverse event reports
- Compounded tirzepatide: more than 730 adverse event reports
Those products were at least made by licensed pharmacies. Cagrilintide does not even have that pathway — it comes from the same unregulated supply chain.
[A supply chain case that already happened]
In 2026, six Australian patients developed liver injury after using products labelled as retatrutide. Those products came from the same grey supply chain. The problem is not the molecule; it is what is actually in the vial.
[Four layers of vial risk]
First, purity. The label says 99%; what is actually in the vial has not been independently verified. Third-party testing is possible, but the buyer has to arrange and pay for it.
Second, endotoxins. This is one of the most critical safety markers for injectable products. Endotoxin contamination can cause fever, chills and, in severe cases, shock. Grey-market vials rarely come with endotoxin testing reports.
Third, label accuracy. How many milligrams are actually in the vial versus what the label claims. Underdosing affects efficacy; overdosing increases adverse event risk.
Fourth, sterility. Injectable products manufactured or aliquoted under non-sterile conditions carry an infection risk.
[The extra risk with premixed vials]
Cagrilintide and retatrutide premixes are typically 12.5 mg retatrutide to 2.5 mg cagrilintide — a 5:1 ratio.
That ratio carries three problems:
First, it is not a ratio used in any clinical trial. In trials, the two drugs were administered separately and titrated separately.
Second, you cannot adjust one independently. To change cagrilintide, you must change retatrutide.
Third, if nausea appears, you cannot tell which peptide caused it.
There is a more basic problem underneath: does the ratio on the label match the ratio in the powder? No independent testing of cagrilintide-retatrutide mixtures has been conducted and published.
[What the research-use label actually means]
"Research use only" is a defined regulatory category. It means the product is not for human or animal use, only for laboratory research.
That label provides no quality assurance. It does not mean the product has been tested to injectable-grade standards, does not mean it is sterile, and does not mean endotoxin limits are met.
In its March 2026 warning letters, the FDA made clear it will judge a product's intended use from website content, and that disclaimers on the label provide no protection.
[Conclusion]
The core grey-market risk with cagrilintide is not the molecule but the supply chain: purity, endotoxins, label accuracy, sterility and premix ratio — none of which is independently verified.
What has already happened: on the same supply chain, products labelled as retatrutide caused liver injury in six Australian patients, and compounded GLP-1 drugs have generated nearly a thousand adverse event reports.
If risk must be assessed, the documented harm record comes entirely from adjacent products, while cagrilintide itself has no independent third-party testing data at all.